The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]

Alexander Kulik¹ , Michel Le May² , George A Wells³ , Thierry G Mesana⁴ and Marc Ruel⁵

¹Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Canada

²Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Canada

³Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada

⁴Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Canada

⁵Division of Cardiac Surgery, University of Ottawa Heart Institute, and Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada

author email corresponding author email

Current Controlled Trials in Cardiovascular Medicine 2005, 6:15doi:10.1186/1468-6708-6-15


Published:	11 October 2005

Abstract

Background

Saphenous vein graft disease remains a major limitation of coronary artery bypass graft surgery. The process of saphenous vein intimal hyperplasia begins just days after surgical revascularization, setting the stage for graft atherosclerotic disease and its sequalae. Clopidogrel improves outcomes in patients with atherosclerotic disease, and is effective at reducing intimal hyperplasia in animal models of thrombosis. Therefore, the goal of this study will be to evaluate the efficacy of clopidogrel and aspirin therapy versus aspirin alone in the prevention of saphenous vein graft intimal hyperplasia following coronary artery bypass surgery.

Methods

Patients undergoing multi-vessel coronary artery bypass grafting and in whom at least two saphenous vein grafts will be used are eligible for the study. Patients will be randomized to receive daily clopidogrel 75 mg or placebo, in addition to daily aspirin 162 mg, for a one year duration starting on the day of surgery (as soon as postoperative bleeding has been excluded). At the end of one year, all patients will undergo coronary angiography and intravascular ultrasound assessment of one saphenous vein graft as selected by randomization. The trial will be powered to test the hypothesis that clopidogrel and aspirin will reduce vein graft intimal hyperplasia by 20% compared to aspirin alone at one year following bypass surgery.

Discussion

This trial is the first prospective human study that will address the question of whether clopidogrel therapy improves outcomes and reduces saphenous vein graft intimal hyperplasia following cardiac surgery. Should the combination of clopidogrel and aspirin reduce the process of vein graft intimal hyperplasia, the results of this study will help redefine modern antiplatelet management of coronary artery bypass patients.